|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2.
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Hollingsworth HC, Kohn EC, Steinberg SM,
Rothenberg ML and Merino MJ: Tumor angiogenesis in advanced stage
ovarian carcinoma. Am J Pathol. 147:33–41. 1995.PubMed/NCBI
|
|
4.
|
Cannistra SA, Matulonis UA, Penson RT, et
al: Phase II study of bevacizumab in patients with
platinum-resistant ovarian cancer or peritoneal serous cancer. J
Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
|
|
5.
|
Capizzi RL, Bertino JR, Skeel RT, et al:
L-asparaginase: clinical, biochemical, pharmacological, and
immunological studies. Ann Intern Med. 74:893–901. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Clarkson B, Krakoff I, Burchenal J, et al:
Clinical results of treatment with E. coliL-asparaginase in
adults with leukemia, lymphoma, and solid tumors. Cancer.
25:279–305. 1970.
|
|
7.
|
Haskell CM, Canellos GP, Cooney DA and
Hansen HH: Biochemical and pharmacologic effects of L-asparaginase
in man. J Lab Clin Med. 75:763–770. 1970.PubMed/NCBI
|
|
8.
|
Haskell CM, Canellos GP, Leventhal BG, et
al: L-asparaginase: therapeutic and toxic effects in patients with
neoplastic disease. N Engl J Med. 281:1028–1034. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Lorenzi PL, Llamas J, Gunsior M, et al:
Asparagine synthetase is a predictive biomarker of L-asparaginase
activity in ovarian cancer cell lines. Mol Cancer Ther.
7:3123–3128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lorenzi PL, Reinhold WC, Rudelius M, et
al: Asparagine synthetase as a causal, predictive biomarker for
L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther.
5:2613–2623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Taylor CW, Dorr RT, Fanta P, Hersh EM and
Salmon SE: A phase I and pharmacodynamic evaluation of polyethylene
glycol-conjugated L-asparaginase in patients with advanced solid
tumors. Cancer Chemother Pharmacol. 47:83–88. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Yu M, Henning R, Walker A, et al:
L-asparaginase inhibits invasive and angiogenic activity and
induces autophagy in ovarian cancer. J Cell Mol Med. 16:2369–2378.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Graham ML: Pegaspargase: a review of
clinical studies. Adv Drug Deliv Rev. 55:1293–1302. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ho DH, Brown NS, Yen A, et al: Clinical
pharmacology of polyethylene glycol-L-asparaginase. Drug Metab
Dispos. 14:349–352. 1986.PubMed/NCBI
|
|
15.
|
Simon R: Optimal two-stage designs for
phase II clinical trials. Control Clin Trials. 10:1–10. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
17.
|
Rose PG, Tian C and Bookman MA: Assessment
of tumor response as a surrogate endpoint of survival in
recurrent/platinum-resistant ovarian carcinoma: a Gynecologic
Oncology Group study. Gynecol Oncol. 117:324–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Guarnaccia C, Fabbiano F and Mancuso L:
Pulmonary embolism and L-asparaginase therapy. Acta Haematol.
71:2151984. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Pitney WR, Phadke KP and Dean S:
Antithrombin III deficiency during asparaginase therapy. Lancet.
1:493–494. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Vellenga E, Mulder NH and Nieweg HO:
Antithrombin III deficiency during asparaginase therapy. Lancet.
1:649–650. 1980. View Article : Google Scholar : PubMed/NCBI
|
